Amneal Pharmaceuticals (AMRX) Research & Development (2017 - 2026)

Amneal Pharmaceuticals' Research & Development history runs 10 years deep, the most recent figure standing at $38.4 million for Q1 2026.

• In Q1 2026, Research & Development fell 4.14% year-over-year to $38.4 million; the TTM figure through Mar 2026 stood at $184.5 million (down 3.62% YoY), while the FY2025 annual figure was $186.2 million, down 2.38% from the prior year.
• Research & Development was $38.4 million for Q1 2026 at Amneal Pharmaceuticals, up from $34.8 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $63.4 million in Q3 2025 to a low of $34.8 million in Q4 2025.
• Historically, Research & Development has averaged $45.6 million across 5 years, with a median of $41.9 million in 2022.
• The sharpest annual moves came in 2024 and 2025: Research & Development soared 47.67% in 2024, then sank 35.84% in 2025.
• A 5-year view of Research & Development shows it stood at $41.9 million in 2022, then advanced by 9.97% to $46.1 million in 2023, then advanced by 17.75% to $54.3 million in 2024, then sank by 35.84% to $34.8 million in 2025, then rose by 10.24% to $38.4 million in 2026.
• The last three Research & Development figures came in at $38.4 million (Q1 2026), $34.8 million (Q4 2025), and $63.4 million (Q3 2025), per Business Quant data.